Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Combined vaccine (4-in-1)

Diphtheria with tetanus, pertussis and poliomyelitis vaccine

Brand names: Boostrix-IPV, Repevax

This is a combined diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis (DTaP/IPV) vaccine, used in the UK as the pre-school booster and, in a low-dose form, in pregnancy for pertussis protection of the newborn.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Diphtheria and tetanus toxoids, acellular pertussis components and inactivated poliovirus stimulate protective immunity against each of the four diseases.

Prescribing in practice

  • Withhold in anyone with anaphylaxis to a previous dose or component; an unstable or evolving neurological condition warrants specialist advice before pertussis-containing vaccine.
  • Administer intramuscularly and ensure the correct antigen strength for the indication, as the pre-school booster differs from any lower-dose pertussis preparation used antenatally.
  • Postpone for acute febrile illness but do not delay for minor coughs and colds.

Monitoring

Observe for immediate allergic reactions after injection and counsel on common transient local and febrile reactions.

Counselling the patient

  • Local soreness and mild fever are expected and short-lived.
  • Report any high fever, persistent crying or unusual reaction.
  • Bring the red book so the dose can be recorded.

Evidence & guidelines

DTaP/IPV is the recommended pre-school booster in the UK routine childhood immunisation schedule per national guidance (the Green Book).

Reference: UKHSA Green Book; NHS England immunisation schedule; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways